ERS Genomics
88 Harcourt Street
Dublin 2
Tel: +353-01-539-0082
Website: http://www.ersgenomics.com/
Email: info@ersgenomics.com
About ERS Genomics
ERS Genomics was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property held by co-inventor and co-owner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use.CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods.
YEAR FOUNDED:
2013
LEADERSHIP:
Scientific Advisor and Co-Founder: Dr. Emmanuelle Charpentier
Chairman of the Board and Co-Founder: Shaun Foy
CEO: Eric Rhodes
TECHNOLOGY:
Please click here for ERS Genomics' technology.
67 articles about ERS Genomics
-
Taconic Biosciences Secures CRISPR License From ERS Genomics
5/31/2017
-
Oxford Genetics Licenses CRISPR Gene Editing Technology From ERS Genomics To Extends Its Synthetic Biology Capabilities
5/9/2017
-
Patent Fight Continues as CRISPR, Intellia, Caribou Biosciences and ERS Genomics Appeal CRISPR Decision
4/13/2017
-
ERS Genomics Release: European Patent Office To Grant Broad Claims On Patent Covering CRISPR-Cas9 Gene Editing Technology
3/28/2017
-
CRISPR, Intellia, Caribou Biosciences And ERS Genomics Provide Update On CRISPR/Cas9 U.S. Patent Interference Proceedings And Grants Of Corresponding Patents In The U.K.
2/16/2017
-
ERS Genomics And Knudra Transgenics Sign License Agreement On CRISPR-Cas9 Genome Editing Patents For Model-Organisms
11/2/2016
-
ERS Genomics And Evolva Sign License Agreement On CRISPR-Cas9 Genome Editing Patents For Industrial Applications
10/27/2016